A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Administered By

Awarded By

Contributors

Start/End

  • June 27, 2016 - May 9, 2018